2月26日，中慧生物发布盈喜公告：2025年，公司预计实现年度收入4.46亿元至4.93亿元，同比增长 71.8%至89.9%;公司预期当期将录得净亏损约1.57亿元至1.97亿元，同比显著收窄约23.9%至39.3%。 从二级市场角度来看，随着中慧生物被纳入新一轮港股通标的名单，市场对公司的关注度出现明显提 升。智通财经APP观察到，今年1月，国海证券发布研报首次覆盖中慧生物，给予公司"增持"评级;而在 股价层面，在去年股价累涨逾200%后，中慧生物股价今年年初至今的上涨幅度再超30%，反映出场内 持续高涨的交投热情以及投资者对公司长期价值的认可。 而此次中慧生物披露年度业绩盈喜，进一步提高了公司长期增长确定性，表明公司在专注创新疫苗升级 的同时，已进入商业化兑现期，有望迎来业绩与估值双重提升的"戴维斯双击"。 商业化能力再获验证，"投资确定性"进一步提升 今年以来，中慧生物股价走出一段"小高潮"，最高股价达到59.90港元，较公司上市发行价上涨逾 360%，但该表现本质上体现的是中慧生物深耕创新疫苗战略下的阶段性成果。而其中的关键载体，便 是逐渐获得商业化验证的核心品种——四价流感病毒亚单位疫苗慧尔康欣® ...

Core Viewpoint - The market's expectation for the Federal Reserve to lower interest rates in September is increasing, which is likely to attract more global capital into the Hong Kong pharmaceutical sector, particularly benefiting companies like Zhonghui Biopharma [1] Company Performance - Zhonghui Biopharma reported a revenue of 71.12 million yuan for the first half of 2025, representing a significant year-on-year increase of 919.25%, indicating strong market recognition of its core product, the Huili Kangxin® vaccine [2] - In contrast, competitors such as Wantai Biologics and Kanglaite reported declines in revenue and net profit, highlighting Zhonghui's strong performance amidst a challenging industry environment [2] Product Innovation - Huili Kangxin® is the first and only approved quadrivalent influenza virus subunit vaccine in China, showing high purity and low adverse reaction risks, with seroprotection rates exceeding EU standards [3] - The vaccine has demonstrated strong immune response capabilities, with seroprotection rates against various virus strains ranging from 89.41% to 97.98% [3] Research and Development - Zhonghui Biopharma has invested 98.84 million yuan in R&D in the first half of the year, supporting its innovative vaccine development and enhancing its product pipeline, which includes 11 other vaccines in various stages of research [6] - The company has received IND approval for a recombinant respiratory syncytial virus vaccine, marking a significant milestone in its R&D efforts [7] Production Capacity - The company is expanding its production capacity with a facility in Taizhou, Jiangsu, featuring multiple GMP-compliant production lines for various vaccines, ensuring sufficient capacity for future growth [8] - Huili Kangxin® has been adopted in over 30 provinces in China, with a 100% approval rate for product quality and registration [8] Strategic Expansion - Zhonghui Biopharma is pursuing international market registrations and strategic acquisitions, with plans to submit applications in several countries, including Thailand and Canada, to enhance its global footprint [9] - The company has allocated over 10% of its IPO funds for strategic acquisitions, aiming to shorten market entry timelines in Southeast Asia [9]

Core Viewpoint - Zhonghui Biotech is facing a significant challenge in balancing its technological advantages with market realities, particularly with its high-priced quadrivalent influenza vaccine, Huiliankangxin® [1] Group 1: Product and Market Position - Huiliankangxin® demonstrates a serum protection rate of 96.56%-97.98% against four major virus strains, exceeding EU standards and showing better safety than mainstream split vaccines [2] - The pricing of Huiliankangxin® at 319 yuan per dose is considered "luxury" in a competitive market where major players like Hualan Bio and Sinovac have priced their quadrivalent vaccines between 78-150 yuan [2] Group 2: Commercialization Challenges - The company missed the peak sales period as Huiliankangxin® only received its first batch approval in June, while competitors like Sinovac had already captured the market by Q1 [3] - Despite covering 30 provinces and 1,100 disease control centers, the company reported a revenue of only 41,300 yuan in Q1 2025, highlighting significant seasonal weaknesses in its commercialization capabilities [3] - For 2024, although revenue is projected to increase by 397.65% to 260 million yuan, sales expenses surged by 153% to 140 million yuan, alongside 206 million yuan in R&D costs, leading to a net loss of 259 million yuan [3] Group 3: Valuation Concerns - Zhonghui Biotech's price-to-sales (PS) ratio stands at 16.1 times based on the last financing round valuation of 4.189 billion yuan, which is 113% higher than the industry average of 7.55 times [4] - The current market sentiment is shifting towards a more rational evaluation of companies, particularly those with strong technology but struggling with commercialization, indicating a potential reevaluation of their valuations [4]